Ebiratide

Summary

Ebiratide (also known as Hoe 427) is a synthetic hexapeptide analogue of ACTH(4-9). It was investigated primarily for its neurotrophic and neuroprotective properties, including potential enhancement of learning, memory, and nerve regeneration. Unlike full-length ACTH, ebiratide has minimal steroidogenic activity and acts centrally. Research interest focused on cognitive enhancement and peripheral neuropathy, but it did not advance to approved clinical use.

Mechanism of Action

Synthetic analogue of ACTH(4-9) that acts on melanocortin receptors (MC1R, MC3R, MC4R) and potentially other CNS receptors; modulates neurotrophic and cognitive processes without significant adrenocortical stimulation.

Routes of Administration

Goals & Uses

• NeuroprotectionNeurologyLow
• Cognitive enhancement / memory improvementNeurologicalLow
• Attention and concentration improvementCognitiveLow
• Peripheral nerve regenerationNeurologicalLow

Contraindications

• Known hypersensitivity to ACTH analoguesAllergyHigh

Adverse Effects

• Transient blood pressure changesCardiovascularRare
• Injection site reactionsLocalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit

Drug Interactions

• CorticosteroidsLow

Population Constraints

• Patients with adrenal tumorsOncologyRelative
• Pediatric patientsAgeRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedDeveloped by Hoechst (Germany) but did not reach marketing authorization; research compound.
• United StatesUnapprovedNever submitted for or received FDA approval; research use only.
• United KingdomUnapprovedNo MHRA approval; research use only.

Ebiratide has not received regulatory approval in any major jurisdiction. It remains a research compound studied in preclinical and early clinical settings.

Evidence & Sources

No sources recorded yet.